Skip to main content

Table 2 Characteristics of study participants

From: Markers of sulfadoxine–pyrimethamine resistance in Eastern Democratic Republic of Congo; implications for malaria chemoprevention

 

Baraka

Kimbi

Walikale

Mweso

Suspected clinical malaria

500

415

662

330

Antenatal visits

169

151

73

121

Age, % (n)

 < 2 years

19.9 (133)

21.8 (123)

14.3 (105)

12.0 (54)

 2–4 years

20.9 (140)

30.3 (171)

17.1 (125)

13.1 (59)

 5–9 years

17.2 (115)

2.1 (12)

17.9 (131)

13.3 (60)

 10–14 years

6.4 (43)

1.6 (9)

14.6 (107)

11.3 (51)

 ≥ 15 years

35.6 (238)

44.2 (249)

36.2 (265)

50.3 (227)

Parasite prevalence RDT, % (n/N)

 Clinic

47.2 (236/500)

50.6 (210/415)

64.1 (424/662)

51.8 (171/330)

 ANC

9.5 (16/169)

32.5 (49/151)

50.7 (37/73)

14.1 (17/121)

Parasite prevalence qPCR, % (n/N)

 Clinic

81.2 (406/500)

74.9 (311/415)

79.8 (528/662)

73.3 (242/330)

 ANC

41.4 (70/169)

64.9 (98/151)

57.5 (42/73)

32.2 (39/121)

  1. Clinic samples from individuals attending the clinic with suspected clinical malaria, ANC samples from individuals attending antenatal care, RDT rapid diagnostic test SD Bioline, qPCR quantitative polymerase chain reaction, n absolute number, N total sample size per location